Lam John S, Klatte Tobias, Breda Alberto
Roy and Patricia Disney Family Cancer Center, Providence Saint Joseph Medical Center, Burbank, CA 91505, USA.
Indian J Urol. 2009 Oct-Dec;25(4):446-54. doi: 10.4103/0970-1591.57906.
The most important and widely utilized system for providing prognostic information following surgical management for renal cell carcinoma (RCC) is currently the tumor, nodes, and metastasis (TNM) staging system. An accurate and clinically useful staging system is an essential tool used to provide patients with counseling regarding prognosis, select treatment modalities, and determining eligibility for clinical trials. Data published over the last few years has led to significant controversies as to whether further revisions are needed and whether improvements can be made with the introduction of new, more accurate predictive prognostic factors. Staging systems have also evolved with an increase in the understanding of RCC tumor biology. Molecular tumor biomarkers are expected to revolutionize the staging of RCC by providing more effective prognostic ability over traditional clinical variables alone. This review will examine the components of the TNM staging system, current staging modalities including comprehensive integrated staging systems, and predictive nomograms, and introduce the concept of molecular staging for RCC.
目前,用于提供肾细胞癌(RCC)手术治疗后预后信息的最重要且应用最广泛的系统是肿瘤、淋巴结和转移(TNM)分期系统。准确且临床实用的分期系统是用于为患者提供预后咨询、选择治疗方式以及确定临床试验资格的重要工具。过去几年发表的数据引发了关于是否需要进一步修订以及引入新的、更准确的预测预后因素是否能带来改善的重大争议。随着对RCC肿瘤生物学认识的增加,分期系统也在不断演变。分子肿瘤生物标志物有望通过单独提供比传统临床变量更有效的预后能力,彻底改变RCC的分期。本综述将审视TNM分期系统的组成部分、当前的分期方式,包括综合集成分期系统和预测列线图,并介绍RCC分子分期的概念。